Baker Bros. Advisors LP has maintained an active but balanced trading approach across its portfolio, with 112 transactions spanning nine companies in recent filings. The firm has executed $346.3 million in buys against $328.6 million in sells, reflecting a modest net accumulation strategy. Recent activity shows a clear pivot toward purchasing, with 20 buy transactions and zero sells since November 2025. The most significant acquisitions include a $158.1 million position in Kymab Ltd (KYMR) and a $36.6 million stake in Denali Therapeutics (DNLI), both established through private placements on December 11, 2025. These were complemented by a $55 million investment in Kodiak Sciences (KOD) on December 18, 2025, structured across two separate transactions.
Smaller but repeated purchases in TRDA (now trading as Entrada Therapeutics) between November 10-20, 2025, ranging from $21,290 to $625,331 per transaction, suggest ongoing accumulation in the biotech firm. The absence of sales during this period contrasts with earlier balanced activity, indicating a potential shift in portfolio strategy. While recent Form 4 filings for DBVT (DBV Technologies) and BCYC (Bicycle Therapeutics) in January 2026 show acquisitions with undisclosed values, the firm’s overall pattern demonstrates concentrated buying in late-stage biopharma names, particularly through private placements. The lack of monetization events in recent months bears watching for whether this represents a temporary pause or a longer-term holding strategy.
AI-assisted summary